Intellia Therapeutics (NTLA) Profit After Tax (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Profit After Tax data on file, last reported at -$96.2 million in Q1 2026.

• On a quarterly basis, Profit After Tax rose 15.5% year-over-year to -$96.2 million in Q1 2026; TTM through Mar 2026 was -$395.0 million, a 24.68% increase from a year earlier, with the FY2025 full-year figure at -$412.7 million, up 20.49% from the prior year.
• Profit After Tax for Q1 2026 stood at -$96.2 million, roughly flat from -$96.2 million in the prior quarter.
• Over the last five years, Profit After Tax for NTLA reached as high as -$96.2 million in Q4 2025 and fell as low as -$147.0 million in Q2 2024.
• Historically, Profit After Tax has averaged -$116.5 million across 5 years, with a median of -$113.4 million in 2022.
• Across the five-year window, Profit After Tax sank 217.87% in 2022 and jumped 31.11% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$113.4 million in 2022, then dropped by 15.38% to -$130.8 million in 2023, then dropped by 1.13% to -$132.3 million in 2024, then gained by 27.32% to -$96.2 million in 2025, then fell by 0.06% to -$96.2 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$96.2 million in Q1 2026, -$96.2 million in Q4 2025, and -$101.3 million in Q3 2025.